Novartis AG
DUS:NOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novartis AG
DUS:NOT
|
CH |
|
Nekkar ASA
F:0TT
|
NO |
|
A
|
ALT Telecom PCL
SET:ALT
|
TH |
|
Renew Holdings PLC
F:LLP
|
UK |
|
National Bankshares Inc
F:9F2
|
US |
|
P
|
PLDT Inc
F:PLO
|
PH |
Intrinsic Value
Is NOT undervalued or overvalued?
See the intrinsic value estimate for 
Novartis AG and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
NOT looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with NOT’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Novartis Does
Novartis AG is a global drugmaker that discovers, develops, manufactures, and sells prescription medicines. Its main products are branded treatments for serious illnesses, including cancer, immune diseases, heart and kidney conditions, eye disease, and some rare disorders. It does not sell everyday consumer health products; its business is centered on medicines that doctors prescribe to patients.
- Headquarters
- Switzerland CH
- Employees
- 75 267
- IPO date
- May 7, 2001
Novartis has no economic moat
Patent protection keeps copies of individual Novartis medicines out temporarily, but it does not permanently prevent competitors from taking sales. Generic competition affecting medicines such as Entresto and Tasigna shows why successful products alone do not ensure lasting protection across the company.
Read the full moat analysis
Revenue & Expenses Breakdown
Novartis AG
Earnings Waterfall
Novartis AG
The intrinsic value for Novartis AG (NOT) under the Base Case is hidden EUR.
Compared with the current market price of 140.12 EUR, the stock appears hidden.